Marker Therapeutics, Inc. Profile Avatar - Palmy Investing

Marker Therapeutics, Inc.

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indic…

Biotechnology
US, Houston [HQ]
Revenue Breakdowns

Segment Analysis Beta

The financial segments are sourced from the SEC' 10-K statement.

Revenue By Top Segments

Marker Therapeutics, Inc. can't present it's sankey chart.

Historical Revenue By Segment

Last 3Y, in million USD

Marker Therapeutics, Inc. can't present revenue by segment

Get PRO Today

With PRO you can bypass the blur for the segment revenues of Marker Therapeutics, Inc..

If you want to see a demo, head over to the financial segments of AAPL

End of MRKR's Analysis
CIK: 1094038 CUSIP: 57055L107 ISIN: US57055L2060 LEI: - UEI: -
Secondary Listings
MRKR has no secondary listings inside our databases.